Healthcare EDI Market Is Witnessing Massive Growth As Siemens Healthineers Partners With Geisinger To Drive Digital Health Collaborations Including AI-Enabled Applications

 


Healthcare EDI or Electronic Data Interchange was conceptualized to build a database that would enable shared access to health information from multiple locations. It makes it possible to exchange the same data between the different entities involved in the care of patients such as doctors, nurses, and other health care providers. In essence, EDI breaks down the physical and financial boundaries that are set between the various parties involved in a health care organization. The adoption of healthcare EDI solutions has witnessed massive growth in developed economies such as the U.S. and Canada. This is due to the fact that there is high demand for innovative IT solutions to streamline workflows combined with increasing regulatory requirements related to patient safety.

As time changes, healthcare organizations are adapting to newer technologies, in order to cater to changing demands. Big data adoption is one of those advanced technologies that has witnessed rising adoption among healthcare companies. Big tech companies are offering novel big data solutions to cater to the demands of healthcare organizations. Recently, in December 2020, Amazon Web Services (AWS) launched Amazon HealthLake, a HIPAA-eligible service that aims to support interoperability standards and boost the use of big data analytics in healthcare. Such factors can stimulate growth of the healthcare EDI market in the near future.

Despite offering numerous advantages, there are concerns regarding data privacy and security. Furthermore, the implementation cost of EDI is significantly high, which could limit growth of the healthcare EDI market. However, many healthcare organizations have found a solution for these adversities such as outsourcing it, which could present lucrative growth opportunities for market players.

Healthcare EDI allows for greater sharing of information that could help in the prevention and treatment of diseases. This is the biggest advantage of EDI over other traditional modes of patient information exchange like direct patient records (DPR). EDI will have to support all types of data interchange so it is important to establish a standard format. These healthcare organizations and healthcare providers are focused on controlling healthcare costs. Healthcare electronic data interchange (HDI) can help organizations to transmit data back and forth using standardized formats. EDI also improves productivity, which enables a higher level of efficiency, accuracy, and speed. Such advantages can boost growth of the healthcare EDI market.

Recently, in June 2020, Siemens Healthineers AG partnered with Geisinger to drive digital health collaborations including AI-enabled applications

 

Comments

Post a Comment

Popular posts from this blog

The Emergence of COVID-19 to Augment Growth of the Outsourced Drug Discovery Market

Image
  With billions of dollars in research and development costs, pharmaceutical companies around the world are always looking for new ways to address their production processes in a cost-effective manner. One way to achieve this is through outsourcing drug discovery and development services. This type of service refers to the collaboration between small and large biotech and biotechnology companies to conduct research and development activities aimed at finding better solutions to the company's core chemical concerns. Outsourcing of these drug discovery services has enabled established pharmaceutical and biotechnology companies to focus on the development of new products that can bring about significant therapeutic change and provide tangible advantages to the company's shareholders. Contract research organizations manage almost all aspects of drug discovery. Market Dynamics I ncreasing demand for outsourcing analytical testing and clinical trial services, growing R&D ex...
Read more

Otoscope Market Is Gaining Major Traction with Industry Leader Otonexus Medical Technologies Introducing Ultrasound Sensor, Which Aids Middle-Ear Infection Diagnosis

Image
  An otoscope or auricular ear picker is a simple health care tool that is used to inspect the outer ear. Many health care professionals utilize otoscopes to examine ear infections during routine check-ups and to also screen for serious ear disorders. An otoscope possibly provides a more detailed view of the external ear canal and/or ear drum or eardrum. Otoscope or also referred to as auriscope is mainly used to look into eyes. The demand for these medical devices has been on a rise in the recent past. This is typically due to the fact that there is a high burden of ENT-related diseases across the globe. As per the World Health Organization (WHO), by 2050, around 2.5 billion people are estimated to have some degree of hearing loss worldwide. Similarly, there is a heavy burden of sinusitis cases. As per the Sinusitis & Allergy Wellness Center, around 30 million adults in the U.S. are impacted with sinusitis annually. Such a high prevalence of ENT disorders has accelerated the d...
Read more

The Number of Cancer Survivors Is Projected To Increase to 22.2 Million By 2030 Fostering Oncology Drug Pipeline Analysis Market

Image
  North America is estimated to dominate the global oncology drug pipeline analysis market in the near future and this is attributed to the high prevalence of cancer and increasing launch of various novel drugs with improved efficacy. According to the National Cancer Institute, as of January 2019, there were an estimated 16.9 million cancer survivors in the United States. The number of cancer survivors is projected to increase to 22.2 million by 2030. The oncology field is experiencing significant growth and this is attributed to the increasing development of various novel therapies for the treatment of cancer. For instance, in February 2021, Rhizen Pharmaceuticals AG, a clinical-stage, oncology-focused biopharma company, with a 50% stake owned by Alembic Pharmaceuticals and the rest by its Indian CEO Swaroop Vakkalanka, has announced that its the novel, next-generation PI3K-delta inhibitor Umbralisib (Ukoniq) has secured U.S. FDA accelerated approval for the treatment of blood c...
Read more